drugset / Trial / NCT04490096
Multimodal Imaging Outcome Measures for ALS (Image ALS)
Phase 1
Terminated
2 enrolled
University of Pennsylvania
Biogen · collabUniversity of Kansas · collabUniversity of Miami · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The primary aim of this study is to determine whether longitudinal neuroimaging acquired across multiple research and clinical centers is a feasible biomarker to use as an outcome measure for clinical trials in amyotrophic lateral sclerosis (ALS)
Timeline
- Start
- 2021-02-25
- Primary completion
- 2022-03-17
- Completion
- 2022-03-17
Outcome
Outcome not reported
Stopped (Business): “Funding issues.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11C-PBR28 | Diagnostic / imaging agent | 20 unknown | Intravenous |